Accès gratuit
Numéro
Med Sci (Paris)
Volume 17, Numéro 11, Novembre 2001
Page(s) 1192 - 1193
Section Nouvelles
DOI http://dx.doi.org/10.1051/medsci/200117111192
Publié en ligne 15 novembre 2001
  1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340 : 1330–40.
  2. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 : 1031–7.
  3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344 : 1038–42.
  4. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL Gene Mutation or Amplification. Science 2001; 293 : 876–80.
  5. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95 : 3498–505.
  6. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95 : 1758–66.
  7. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571 : diverse mechanisms of resistance. Blood 2000; 96 : 1070–9.
  8. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289 : 1938–42.
  9. Hochhaus A, Krei S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293 : 2163a.
  10. Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293 : 2163a.